# US 2005/0037951 A1 · Composition and methods for treatment of sexual dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0037951 A1
- Document ID: US20050037951A1
- Status: Published application
- Kind: A1
- Application number: 10/946,969
- Filed: 2004-09-20
- Published: 2005-02-17
- Earliest claimed: 1999-06-29
- Assignees: Palatin Technologies, Inc.
- Inventors: Christine Blood; Annette Shadiack; Guy Herbert; Joanna Bernstein
- Web page: https://patentgrep.com/patent/US20050037951A1

## CPC

- C07K 14/685: Alpha-melanotropin
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y10S 436/811: Test for named disease, body condition or organ function
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Compositions and methods are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, wherein pharmaceutically sufficient quantities of a linear or cyclic peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and a core His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp sequence are administered. Methods of administration include injection, oral, nasal and mucosal administration.

## Claims

### Claim 1

A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and a core His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide is a linear peptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the peptide is a cyclic peptide.

### Claim 4 (depends on 3)

The method of claim 3, wherein the peptide is cyclicized through a covalent bond comprising two reactive amino acid side chains.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mammal is a male.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mammal is a female.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

The method of claim 1, wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.

### Claim 11

A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a linear peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and including the sequence His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mammal is a male.

### Claim 13 (depends on 11)

The method of claim 11, wherein the mammal is a female.

### Claim 14 (depends on 11)

The method of claim 11, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 15 (depends on 11)

The method of claim 11, wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.

### Claim 16 (depends on 11)

The method of claim 11, wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.

### Claim 18

A method for stimulating sexual response in a mammal, comprising administering a pharmaceutically sufficient amount of a composition comprising a cyclic peptide with a carboxyl terminus —OH group or pharmaceutically acceptable salt thereof and including the sequence His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp sequence.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cyclic peptide is cyclicized through a covalent bond comprising two reactive amino acid side chains.

### Claim 20 (depends on 18)

The method of claim 18, wherein the mammal is a male.

### Claim 21 (depends on 18)

The method of claim 18, wherein the mammal is a female.

### Claim 22 (depends on 18)

The method of claim 18, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 23 (depends on 18)

The method of claim 18, wherein administering comprises administering by a method of administration selected from the group consisting of administration by injection, administration through mucous membranes, buccal administration, oral administration, dermal administration, inhalation administration and nasal administration.

### Claim 24 (depends on 18)

The method of claim 18, wherein administering comprises nasal administration of a metered amount of a formulation comprising an aqueous buffer.

### Claim 25 (depends on 24)

The method of claim 24, wherein the aqueous buffer is a member selected from the group consisting of saline and citrate buffer.
